Variable domain N-linked glycans acquired during antigen-specific immune responses can contribute to immunoglobulin G antibody stability

Frontiers in Immunology

Volumn 9, Issue APR, 2018, Pages

  van de Bovenkamp, Fleur S ^a,b   Derksen, Ninotska I L ^a,b   van Breemen, Mariëlle J ^b   de Taeye, Steven W ^a,b   Ooijevaar de Heer, Pleuni ^a,b   Sanders, Rogier W ^b,c   Rispens, Theo ^a,b  

^a SANQUIN RESEARCH   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Adalimumab; Antibody stability; Fab glycosylation; IVIg; Thermal unfolding; Variable domain glycosylation

Indexed keywords

ADALIMUMAB; CETUXIMAB; GLYCAN; IA ANTIGEN; IMMUNOGLOBULIN G; OMALIZUMAB; SIALIDASE;

AFFINITY CHROMATOGRAPHY; ANTIBODY STABILITY; ANTIGEN BINDING; ARTICLE; BIOLOGICAL FUNCTIONS; DIFFERENTIAL SCANNING CALORIMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE AMPLIFICATION; GENE MUTATION; GENE SEQUENCE; GLYCOSYLATION; IMMUNE RESPONSE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN UNFOLDING;

EID: 85045408154     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2018.00740     Document Type: Article

References (28)

1. van de Bovenkamp FS, Hafkenscheid L, Rispens T, Rombouts Y. The emerging importance of IgG Fab glycosylation in immunity. J Immunol (2016) 196(4):1435-41. doi:10.4049/jimmunol.1502136
2. Dunn-Walters D, Boursier L, Spencer J. Effect of somatic hypermutation on potential N-glycosylation sites in human immunoglobulin heavy chain variable regions. Mol Immunol (2000) 37(3-4):107-13. doi:10.1016/S0161-5890(00)00038-9
3. van de Bovenkamp FS, Derksen NIL, Ooijevaar-de Heer P, van Schie KA, Kruithof S, Berkowska MA, et al. Adaptive antibody diversification through N-linked glycosylation of the immunoglobulin variable region. Proc Natl Acad Sci U S A (2018) 115(8):1901-6. doi:10.1073/pnas.1711720115
4. Bohne A, Lang E, von der Lieth CW. SWEET-WWW-based rapid 3D construction of oligo-and polysaccharides. Bioinformatics (1999) 15(9):767-8. doi:10.1093/bioinformatics/15.9.767
5. Holm E, Sletten K, Husby G. Structural studies of a carbohydrate-containing immunoglobulin-lambda-light-chain amyloid-fibril protein (AL) of variable subgroup III. Biochem J (1986) 239(3):545-51. doi:10.1042/bj2390545
6. Middaugh CR, Litman GW. Atypical glycosylation of an IgG monoclonal cryoimmunoglobulin. J Biol Chem (1987) 262(8):3671-3
7. Karimi M, Sletten K, Westermark P. Biclonal systemic AL-amyloidosis with one glycosylated and one nonglycosylated AL-protein. Scand J Immunol (2003) 57(4):319-23. doi:10.1046/j.1365-3083.2003.01230.x
8. Courtois F, Agrawal NJ, Lauer TM, Trout BL. Rational design of therapeutic mAbs against aggregation through protein engineering and incorporation of glycosylation motifs applied to bevacizumab. MAbs (2016) 8(1):99-112. doi:10.1080/19420862.2015.1112477
9. Wu SJ, Luo J, O'Neil KT, Kang J, Lacy ER, Canziani G, et al. Structure-based engineering of a monoclonal antibody for improved solubility. Protein Eng Des Sel (2010) 23(8):643-51. doi:10.1093/protein/gzq037
10. Pepinsky RB, Silvian L, Berkowitz SA, Farrington G, Lugovskoy A, Walus L, et al. Improving the solubility of anti-LINGO-1 monoclonal antibody Li33 by isotype switching and targeted mutagenesis. Protein Sci (2010) 19(5):954-66. doi:10.1002/pro.372
11. Julian MC, Li L, Garde S, Wilen R, Tessier PM. Efficient affinity maturation of antibody variable domains requires co-selection of compensatory mutations to maintain thermodynamic stability. Sci Rep (2017) 7:1-13. doi:10.1038/srep45259
12. Kruijsen D, Einarsdottir HK, Schijf MA, Coenjaerts FE, van der Schoot EC, Vidarsson G, et al. Intranasal administration of antibody-bound respiratory syncytial virus particles efficiently primes virus-specific immune responses in mice. J Virol (2013) 87(13):7550-7. doi:10.1128/JVI.00493-13
13. van Schouwenburg PA, Kruithof S, Votsmeier C, van Schie K, Hart MH, de Jong RN, et al. Functional analysis of the anti-adalimumab response using patient-derived monoclonal antibodies. J Biol Chem (2014) 289(50):34482-8. doi:10.1074/jbc. M114.615500
14. van Schie KA, Ooijevaar-De Heer P, Kruithof S, Plasencia C, Jurado T, Pascual Salcedo D, et al. Infusion reactions during infliximab treatment are not associated with IgE anti-infliximab antibodies. Ann Rheum Dis (2017) 76(7):1285-8. doi:10.1136/annrheumdis-2016-211035
15. Dekkers G, Plomp R, Koeleman CA, Visser R, von Horsten HH, Sandig V, et al. Multi-level glyco-engineering techniques to generate IgG with defined Fc-glycans. Sci Rep (2016) 6. doi:10.1038/srep36964
16. Nagelkerke SQ, Dekkers G, Kustiawan I, van de Bovenkamp FS, Geissler J, Plomp R, et al. Inhibition of Fc R-mediated phagocytosis by IVIg is independent of IgG-Fc sialylation and Fc RIIb in human macrophages. Blood (2014) 124(25):3709-18. doi:10.1182/blood-2014-05-576835
17. Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science (2006) 313(5787):670-3. doi:10.1126/science.1129594
18. Käsermann F, Boerema DJ, Rüegsegger M, Hofmann A, Wymann S, Zuercher AW, et al. Analysis and functional consequences of increased Fab-sialylation of intravenous immunoglobulin (IVIG) after lectin fractionation. PLoS One (2012) 7(6):e37243. doi:10.1371/journal.pone.0037243
19. Guhr T, Bloem J, Derksen NI, Wuhrer M, Koenderman AH, Aalberse RC, et al. Enrichment of sialylated IgG by lectin fractionation does not enhance the efficacy of immunoglobulin G in a murine model of immune thrombocytopenia. PLoS One (2011) 6(6):e21246. doi:10.1371/journal.pone.0021246
20. Stadlmann J, Weber A, Pabst M, Anderle H, Kunert R, Ehrlich HJ, et al. A close look at human IgG sialylation and subclass distribution after lectin fractionation. Proteomics (2009) 9(17):4143-53. doi:10.1002/pmic.200800931
21. Bondt A, Rombouts Y, Selman MH, Hensbergen PJ, Reiding KR, Hazes JM, et al. Immunoglobulin G (IgG) Fab glycosylation analysis using a new mass spectrometric high-throughput profiling method reveals pregnancy-associated changes. Mol Cell Proteomics (2014) 13(11):3029-39. doi:10.1074/mcp. M114.039537
22. Easterbrook-Smith SB, Dwek RA. The use of ANS fluorescence as a probe for immunoglobulin flexibility. FEBS Lett (1980) 121(2):253-6. doi:10.1016/0014-5793(80)80355-3
23. Rispens T, Lakemond CMM, Derksen NIL, Aalberse RC. Detection of conformational changes in immunoglobulin G using isothermal titration calorimetry with low-molecular-weight probes. Anal Biochem (2008) 380(2):303-9. doi:10.1016/j.ab.2008.06.001
24. Ericsson UB, Hallberg BM, Detitta GT, Dekker N, Nordlund P. Thermofluor-based high-throughput stability optimization of proteins for structural studies. Anal Biochem (2006) 357(2):289-98. doi:10.1016/j.ab.2006.07.027
25. McConnell AD, Zhang X, Macomber JL, Chau B, Sheffer JC, Rahmanian S, et al. A general approach to antibody thermostabilization. MAbs (2014) 6(5):1274-82. doi:10.4161/mabs.29680
26. de Taeye SW, Ozorowski G, Torrents de la Peña A, Guttman M, Julien JP, van den Kerkhof TL, et al. Immunogenicity of stabilized HIV-1 envelope trimers with reduced exposure of non-neutralizing epitopes. Cell (2015) 163(7):1702-15. doi:10.1016/j.cell.2015.11.056
27. Hintersteiner B, Lingg N, Janzek E, Mutschlechner O, Loibner H, Jungbauer A. Microheterogeneity of therapeutic monoclonal antibodies is governed by changes in the surface charge of the protein. Biotechnol J (2016) 11(12):1617-27. doi:10.1002/biot.201600504
28. Liu J, Eris T, Li C, Cao S, Kuhns S. Assessing analytical similarity of proposed amgen biosimilar ABP 501 to adalimumab. BioDrugs (2016) 30(4):321-38. doi:10.1007/s40259-016-0184-3